Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GEMTUZUMAB OZOGAMICIN Cause Staphylococcal sepsis? 16 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Staphylococcal sepsis have been filed in association with GEMTUZUMAB OZOGAMICIN (Mylotarg). This represents 0.9% of all adverse event reports for GEMTUZUMAB OZOGAMICIN.

16
Reports of Staphylococcal sepsis with GEMTUZUMAB OZOGAMICIN
0.9%
of all GEMTUZUMAB OZOGAMICIN reports
7
Deaths
12
Hospitalizations

How Dangerous Is Staphylococcal sepsis From GEMTUZUMAB OZOGAMICIN?

Of the 16 reports, 7 (43.8%) resulted in death, 12 (75.0%) required hospitalization.

Is Staphylococcal sepsis Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GEMTUZUMAB OZOGAMICIN. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does GEMTUZUMAB OZOGAMICIN Cause?

Febrile neutropenia (412) Pyrexia (138) Sepsis (122) Thrombocytopenia (117) Venoocclusive liver disease (117) Off label use (88) Drug ineffective (87) Death (81) Bone marrow failure (80) Neutropenia (68)

What Other Drugs Cause Staphylococcal sepsis?

CYCLOPHOSPHAMIDE (317) METHOTREXATE (311) RITUXIMAB (246) VINCRISTINE (229) DEXAMETHASONE (199) CYTARABINE (195) PREDNISOLONE (184) METHYLPREDNISOLONE (174) DOXORUBICIN (160) PREDNISONE (157)

Which GEMTUZUMAB OZOGAMICIN Alternatives Have Lower Staphylococcal sepsis Risk?

GEMTUZUMAB OZOGAMICIN vs GEMZAR GEMTUZUMAB OZOGAMICIN vs GENTAMICIN GEMTUZUMAB OZOGAMICIN vs GEODON GEMTUZUMAB OZOGAMICIN vs GILENYA GEMTUZUMAB OZOGAMICIN vs GILOTRIF

Related Pages

GEMTUZUMAB OZOGAMICIN Full Profile All Staphylococcal sepsis Reports All Drugs Causing Staphylococcal sepsis GEMTUZUMAB OZOGAMICIN Demographics